Equity
Share Repurchase Authorization Limit
Royalty Pharma Share Repurchase Authorization Limit decreased by 10.5% to $1.70B in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ4 2016
Last reportedQ4 2024
How to read this metric
Higher limits suggest strong cash flow and management's belief that the stock is undervalued.
Detailed definition
This is the maximum dollar value or share count authorized by the Board of Directors for the repurchase of the company's...
Peer comparison
Common among mature, cash-generative companies seeking to optimize their capital structure.
Metric ID:
share_repurchase_authorization_limitHistorical Data
4 periods
| Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|
| Value | $2.30B | $2.00B | $1.90B | $1.70B |
| QoQ Change | — | -13.0% | -5.0% | -10.5% |
| YoY Change | — | — | — | -26.1% |
Range$1.70B – $2.30B
Avg YoY Growth-26.1%
Median YoY Growth-26.1%
Current Streak3+ quarters decline
Share Repurchase Authorization Limit at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's share repurchase authorization limit?
- Royalty Pharma (RPRX) reported share repurchase authorization limit of $1.70B in Q1 2026.
- What does share repurchase authorization limit mean?
- The maximum amount the company is allowed to spend on buying back its own stock.